Context: Sclerostin is produced by osteocytes and inhibits bone formation through the Wnt/β-catenin-signaling pathway. Only limited data are available on circulating sclerostin levels in healthy subjects.

Objective: We aimed to evaluate the correlation between sclerostin and physical activity, anthropometric, and biochemical variables.

Design, Setting, And Participants: We conducted a cross-sectional observational study in 161 healthy adult men and premenopausal women aged 19 to 64 yr (mean age, 44 ± 10).

Intervention(s): There were no interventions.

Main Outcome Measure(s): Serum sclerostin levels were associated with body composition, bone mineral density, physical activity, and various biochemical parameters.

Results: A positive correlation between age and sclerostin in both men (r = 0.37; P < 0.001) and premenopausal women (r = 0.66; P < 0.001) was found. Men had significantly higher sclerostin levels than women (49.8 ± 17.6 vs. 37.2 ± 15.2 pmol/liter; P < 0.001). However, after adjustment for age, bone mineral content (BMC), physical activity, body mass index (BMI), and renal function, sclerostin levels did not differ (P = 0.543). Partial correlation analysis adjusted for age, gender, and kidney function revealed a significant positive correlation between sclerostin levels and BMC, bone mineral density, BMI, and android/gynoid fat and a significant negative correlation with serum osteocalcin and calcium. The most physically active quartile had significantly lower sclerostin levels compared to the least active quartile in a univariate analysis.

Conclusions: In healthy adults, sclerostin serum levels correlate positively with age, BMI, and BMC and negatively with osteocalcin and calcium. Further studies in larger populations are needed to confirm our findings and to better understand their clinical implications.

Download full-text PDF

Source
http://dx.doi.org/10.1210/jc.2011-2152DOI Listing

Publication Analysis

Top Keywords

sclerostin levels
24
physical activity
16
bone mineral
16
sclerostin
11
age gender
8
body composition
8
composition bone
8
mineral content
8
healthy adults
8
correlation sclerostin
8

Similar Publications

Role of sclerostin in mastocytosis bone disease.

Sci Rep

January 2025

Department of Haematooncology and Bone Marrow Transplantation, Medical University of Lublin, Lublin, Staszica Street 11, 20-081, Poland.

Mastocytosis is a heterogeneous group of disorders, characterized by accumulation of clonal mast cells which can infiltrate several organs, most often spine (70%). The pathogenesis of mastocytosis bone disease is poorly understood. The main aim of the study was to investigate whether neoplastic mast cells may be the source of sclerostin and whether there is an association between sclerostin and selected bone remodeling markers with mastocytosis related bone disease.

View Article and Find Full Text PDF

Sclerostin as a new target of diabetes-induced osteoporosis.

Front Endocrinol (Lausanne)

December 2024

Department of Endocrinology and Metabolism, Want Want Hospital, Changsha, Hunan, China.

Sclerostin, a protein synthesized by bone cells, is a product of the gene. Sclerostin is a potent soluble inhibitor of the WNT signaling pathway, and is known to inhibit bone formation by inhibiting osteocyte differentiation and function. Currently, sclerostin has been the subject of numerous animal experiments and clinical investigations.

View Article and Find Full Text PDF

Background: There is still a lack of information regarding the impact of sodium-glucose cotransporter 2 inhibitors (SGLT2i) on bone and mineral metabolism in patients with diabetes and chronic kidney disease (CKD). Therefore, we aimed to investigate the effects of SGLT2i in a cohort of patients suffering from diabetic kidney disease (DKD).

Methods: In this prospective observational study, patients with type 2 diabetes and biopsy-proven diabetic nephropathy or presumptive DKD with eGFR levels ≥20 ml/min/1.

View Article and Find Full Text PDF

This study explores how select microRNAs (miRNAs) influence bone structure in humans and in transgenic mice. In trabecular bone biopsies from 84 postmenopausal women (healthy, osteopenic, and osteoporotic), we demonstrate that (deleted in lymphocytic leukemia 2)-encoded is strongly positively associated with bone mineral density (BMD) at different skeletal sites. In bone transcriptome analyses, levels correlated positively with the osteocyte characteristic transcripts (encoding sclerostin) and (Matrix Extracellular Phosphoglycoprotein), while the related showed a negative association with BMD and osteoblast markers.

View Article and Find Full Text PDF
Article Synopsis
  • The study examined the role of Growth differentiation factor (GDF15) in relation to health markers in obese men of different racial and ethnic backgrounds.
  • It involved 193 participants and assessed various health metrics including body composition, hormonal levels, and bone mineral density.
  • Findings indicated that GDF15 levels were higher in non-African Americans than in African Americans, and its relations to glucometabolic status and body composition varied by ethnicity, highlighting potential racial differences in health risks.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!